Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

MDI-based insulin regimen is more cost-effective than CSII

June 7, 2004

Successful islet cell transplantation using the Edmonton protocol

June 7, 2004

Latest phase III data on exenatide in type 2 diabetes presented at ADA

June 7, 2004

New mevastatin derivatives and their use as cholesterol-lowering agents

June 4, 2004

Tanabe Seiyaku claims RANKL antagonists with utility in osteoporosis

June 4, 2004

Nutropin Depot to be discontinued

June 4, 2004

Aventis claims hormone-sensitive lipase inhibitors and their use as antidiabetic agents

June 3, 2004

New cannabinoid CB1 antagonists in early development at Pfizer

June 2, 2004

Zemplar approved for pediatric use

June 1, 2004

Approval for Gonal-f Pen for infertility

June 1, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...